GILD
$137.21-3.90 (-2.76%)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Recent News
Gilead could potentially end HIV. But will it be able to?
After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
A Look At Gilead Sciences (GILD) Valuation As Recent Returns Send Mixed Signals
What recent performance says about Gilead Sciences (GILD) With no single news headline setting the tone, Gilead Sciences (GILD) has still given investors plenty to think about, as the share price and fundamentals paint a mixed, data rich picture. Over the past month the stock shows a return of about a 9% decline, while the past 3 months reflect roughly a 16% gain and the 1 year total return sits near 35%. Longer term shareholders see very large gains, with total returns around 101% over 3...
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $141.29, denoting a -2.15% move from the preceding trading day.
3 Reasons to Avoid GILD and 1 Stock to Buy Instead
Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead Sciences has surged 127% to $145.23 per share. Its momentum hasn’t stopped as it’s also gained 27.8% in the last six months, beating the S&P by 26.8%.